Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products

AYTU BIOPHARMA, INC

Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.
Initial term from Nov 13, 2023 to Nov 13, 2028; auto-renews for successive 3-year terms.
Company must purchase 100% of its requirements for covered products from Halo, except for own manufacturing.
Company supplies active ingredients; Halo handles manufacturing, QC, packaging, and validation.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AYTU BIOPHARMA, INC entered into Commercial Manufacturing Services Agreement with Halo Pharmaceutical, Inc. (effective 2023-11-13).

Action: entry
Agreement: supply
Counterparty: Halo Pharmaceutical, Inc.
Effective: 2023-11-13

Exact text from the filing

On November 13, 2023, Aytu BioPharma, Inc. (the “ Company ”) entered into a Commercial Manufacturing Services Agreement (the “ Agreement ”), with Halo Pharmaceutical, Inc. (“ Halo ”), pursuant to which Halo will manufacture Adzenys XR ODT® and Cotempla XR ODT® products for the Company at Halo’s manufacturing facility.

View on SEC.gov

Browse all material agreements →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-019194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.